Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Arvinas’ layoff announcement drew outsize ... Yale and UConn and larger biotech firms operating in the state like Pfizer and Boehringer Ingelheim help fuel New Haven’s growth, he added. “ ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Arvinas’ most advanced programme is vepdegestrant (ARV-471), in phase 3 for hormone receptor-positive, HER2-negative breast cancer, which was licensed to Pfizer in 2021 for a massive $1 billion ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis ...